Cargando…
Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients
BACKGROUND: Coagulopathies are a major class among COVID-19 associated complications. Although anticoagulants such as unfractionated Heparin and Enoxaparin are both being used for therapeutic mitigation of COVID associated coagulopathy (CAC), differences in their clinical outcomes remain to be inves...
Autores principales: | Pawlowski, Colin, Venkatakrishnan, AJ, Kirkup, Christian, Berner, Gabriela, Puranik, Arjun, O'Horo, John C., Badley, Andrew D., Soundararajan, Venky |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7941023/ https://www.ncbi.nlm.nih.gov/pubmed/33718845 http://dx.doi.org/10.1016/j.eclinm.2021.100774 |
Ejemplares similares
-
Pre-existing conditions are associated with COVID-19 patients’ hospitalization, despite confirmed clearance of SARS-CoV-2 virus
por: Pawlowski, Colin, et al.
Publicado: (2021) -
Enoxaparin may be associated with lower rates of mortality than unfractionated heparin in neurocritical and surgical patients
por: Samuel, Sophie, et al.
Publicado: (2023) -
FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
por: Pawlowski, Colin, et al.
Publicado: (2021) -
Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa
por: Lewis, Joseph, et al.
Publicado: (2022) -
Mapping each pre-existing condition’s association to short-term and long-term COVID-19 complications
por: Venkatakrishnan, A. J., et al.
Publicado: (2021)